Chemomab Therapeutics Ltd
For the period ended Nov 14, 2024. Filed Nov 14, 2024.
View on SEC.govAbout this filing
What a company based outside the US has published at home or sent to its shareholders. It is how many foreign companies share results and news between annual reports.
Nov 14, 2024 · Filed Nov 14, 2024
Use the contents to explore the available documents and sections.
Contents
EXPLANATORY NOTE
On November 14, 2024, Chemomab Therapeutics Ltd. (the “Registrant”) issued a press release titled “Chemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Corporate Update”, a copy of which is furnished as Exhibit 99.1 herewith. Also ,during the third quarter of 2024 , the Company issued 348,554 ADSs at an average price of $1.993 per ADS under its Sales Agreement with Roth Capital Partners, LLC, resulting in gross proceeds of $695 thousand.
The financial information above and the financial information included in the consolidated balance sheets and consolidated statements of operations contained in the press release attached as Exhibit 99.1 to this Report on Form 6-K is hereby incorporated by reference into the Registrant’s Registration Statements on Form F-3 (File No. 333-275002 and 333-281750) and Form S-8 (File No. 333-259489 and No. 333-266868).
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.